Fennec Pharmaceuticals Inc. ( FENC) Stock. Should you Buy or Sell? $ 6.34
-0.54 (-9.31 %)
Fennec Pharmaceuticals Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$47 thousand|
|Market Cap||$164.96 M|
|52 Week Range||$3.822 - $10.078|
Fennec Pharmaceuticals Inc. opened the day at $6.34 which is -9.31 % on yesterday's close. Fennec Pharmaceuticals Inc. has a 52 week high of $10.078 and 52 week low of $3.822, which is a difference of $6.256. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $164.96 M and total net profit is $0 which means the company is trading at inf times profit to market capitalization. Theoretically, if you were to buy Fennec Pharmaceuticals Inc. for $164.96 M, it would take 15 years to get your money back. Fennec Pharmaceuticals Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Fennec Pharmaceuticals Inc. Stock Forecast - Is Fennec Pharmaceuticals Inc. a Buy or Sell?
|DCF Score||Strong Buy|
|ROE Score||Strong Sell|
|ROA Score||Strong Sell|
|PE Score||Strong Sell|
|PB Score||Strong Buy|
Growth and Value
|Net Profit Margin||0.000|
Valuing Fennec Pharmaceuticals Inc.
|Price Book Value Ratio||19.338||Price To Book Ratio||19.338|
|Price To Sales Ratio||0.000||Price Earnings Ratio||-5.451|
How liquid is Fennec Pharmaceuticals Inc.
|Debt Ratio||0.451||Debt Equity Ratio||0.823|
|Long Term Debt To Capitalization||0.318||Total Debt To Capitalization||0.369|
Latest news about Fennec Pharmaceuticals Inc.
PDUFA for Pedmark (sodium thiosulfate) in treating platinum chemotherapy-induced cytotoxicity (ear toxicity) in children is scheduled on September 23. The company resolved the issues raised in the second CRL within 3 months and announced the NDA acceptance in April this year.
100% technical buy signals. 16 new highs and up 22.29% in the last month.
Here is how Adherex Technologies Inc. (FENC) and U.S. Physical Therapy (USPH) have performed compared to their sector so far this year.
The mean of analysts' price targets for Adherex Technologies Inc. (FENC) points to an 80.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
RESEARCH TRIANGLE PARK, N.C., May 23, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.